Exploring Three High Growth Tech Stocks In The United States

The United States market has shown robust performance, climbing by 2.2% over the past week with all sectors experiencing gains, and achieving a 32% increase over the last 12 months, while earnings are projected to grow by 15% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	23.83%	24.32%	★★★★★★
Sarepta Therapeutics	23.90%	42.65%	★★★★★★
Clene	78.50%	60.16%	★★★★★★
TG Therapeutics	34.66%	56.48%	★★★★★★
Alkami Technology	21.89%	98.60%	★★★★★★
Alnylam Pharmaceuticals	22.45%	70.66%	★★★★★★
Travere Therapeutics	31.70%	72.51%	★★★★★★
Blueprint Medicines	25.47%	68.62%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Alnylam Pharmaceuticals (NasdaqGS:ALNY)

Simply Wall St Growth Rating: ★★★★★★

Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutics using ribonucleic acid interference technology, with a market cap of $31.59 billion.

Operations: Alnylam focuses on ribonucleic acid interference therapeutics, generating revenue primarily from its discovery, development, and commercialization activities, totaling $2.09 billion.

Alnylam Pharmaceuticals is navigating a transformative phase with anticipated revenue growth of 22.4% annually, outpacing the US market's average of 8.9%. Despite current unprofitability, the firm is on a trajectory to profitability within three years, supported by robust R&D investments that fuel innovation in RNAi therapeutics. Recent presentations at global healthcare conferences underscore Alnylam's commitment to advancing treatments for ATTR amyloidosis, with promising Phase 3 study results potentially enhancing future revenue streams and strengthening its market position in biotechnology.

• Get an in-depth perspective on Alnylam Pharmaceuticals' performance by reading our health report here.

• Review our historical performance report to gain insights into Alnylam Pharmaceuticals''s past performance.

Gilead Sciences (NasdaqGS:GILD)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines for unmet medical needs globally, with a market cap of $112.40 billion.

Operations: Gilead generates revenue primarily through the discovery, development, and commercialization of innovative medicines, amounting to $28.30 billion. The company operates across the United States, Europe, and internationally.

Gilead Sciences, with a projected annual earnings growth rate of 40.7%, is navigating through a transformative phase despite recent financial setbacks including a significant one-off loss of $10.3B. The company's commitment to innovation is underscored by its R&D focus, where expenses are strategically aligned to foster developments in biotechnology and pharmaceuticals. Recent clinical trial successes, such as the promising results from the Phase 3 ASSURE study for Livdelzi®, highlight Gilead’s potential to enhance its therapeutic offerings and market position significantly. These efforts are part of why Gilead remains a notable entity in the high-growth sectors of tech and healthcare, even as it faces challenges like underperforming revenue growth projections at 2.4% annually compared to broader market averages.

• Click to explore a detailed breakdown of our findings in Gilead Sciences' health report.

• Learn about Gilead Sciences' historical performance.

Globant (NYSE:GLOB)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Globant S.A., along with its subsidiaries, offers technology services globally and has a market cap of $9.89 billion.

Operations: Globant generates revenue primarily from its Software & Programming segment, which brought in $2.35 billion. The company focuses on providing a range of technology services worldwide.

Globant stands out in the tech landscape with its robust revenue growth, projected at 13.2% annually, surpassing the US market average of 8.9%. This growth is complemented by a significant uptick in earnings, expected to rise by 20.1% per year. The company's strategic emphasis on R&D is evident from its recent allocation of substantial resources towards innovation, ensuring it remains at the forefront of technological advancements and competitive within the digital transformation space. Recent collaborations, like with Qiddiya Investment Company to enhance Saudi Arabia’s Qiddiya City through advanced digital ecosystems, underscore Globant’s capability to integrate AI and cloud technologies effectively across global markets. This approach not only solidifies its market position but also aligns with broader industry trends towards immersive technology experiences and smart city developments.

• Click here to discover the nuances of Globant with our detailed analytical health report.

• Understand Globant's track record by examining our Past report.

Next Steps

• Click through to start exploring the rest of the 247 US High Growth Tech and AI Stocks now.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com